Literature DB >> 72237

Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards.

N Zainal, D J Carmichael, J W Griffiths, E M Besterman, P H Kidner, A D Gillham, G D Summers.   

Abstract

Patients with acute myocardial infarction admitted to open wards of three hospitals were given either oral disopyramide (100 mg four times daily) or matching placebo, prophylactically, for seven days. The drug was associated with a significant reduction in mortality (p = 0-0025) and in incidence of extension of infarction (p = 0-01), ventricular fibrillation (p = 0-05), and ventricular tachycardia (p = 0-01). Disopyramide was not associated with any particular complication or side-effect. Unitl information is available to the contrary, oral disopyramide should be given for the first seven days after myocardial infarction to all patients not managed in an intensive-care unit.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 72237     DOI: 10.1016/s0140-6736(77)90829-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Vaginal discharge.

Authors:  A McMillan
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-22

2.  Managing coronaries at home.

Authors: 
Journal:  Br Med J       Date:  1979-06-16

3.  Adverse reaction to disopyramide.

Authors:  J B Dibble; N R Webster
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

4.  Prophylaxis of primary ventricular fibrillation in acute myocardial infarction. The case against lignocaine.

Authors:  P Kertes; D Hunt
Journal:  Br Heart J       Date:  1984-09

5.  Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.

Authors:  C R Kumana; V S Rambihar; K Willis; R N Gupta; P H Tanser; J A Cairns; R A Wildeman; M Johnston; A L Johnson; M Gent
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

6.  Sulphinpyrazone, cardiac infarction, and the prevention of death: a successful trial or another tribulation?

Authors: 
Journal:  Br Med J       Date:  1978-04-15

7.  Some cardiovascular problems with disopyramide.

Authors:  S J Warrington; J Hamer
Journal:  Postgrad Med J       Date:  1980-04       Impact factor: 2.401

8.  Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.

Authors:  R A Allen-Narker; C J Roberts; A J Marshall; S C Jordan; D W Barritt; R M Goodfellow
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 9.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

10.  Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.

Authors: 
Journal:  Postgrad Med J       Date:  1984-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.